PUBLIKATIONEN

Hier finden Sie wissenschaftliche Publikationen der SNEGID-Gruppe. Öffentlich zugängliche Artikel werden als pdf bereitgestellt. Für nicht öffentlich zugängliche Artikel finden Sie den entsprechenden Link.

2023 :

• Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. 
  Arnim UV, et al. Clin Gastroenterol Hepatol 2023;21:2526-2533. doi: 10.1016/j.cgh.2022.12.018.
  
• Dupilumab in Patients with Eosinophilic Esophagitis.
  Greuter T, Schoepfer AM. N Engl J Med 2023;388:955-956. doi: 10.1056/NEJMc2300703.
• Eosinophilic Esophagitis beyond Eosinophils - an Emerging Phenomenon Overlapping with Eosinophilic Esophagitis: Collegium Internationale Allergologicum (CIA) Update 2023.
  Salvador Nunes VS, et al. Int Arch Allergy Immunol 2023;184:411-420. doi: 10.1159/000529910.
• Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis.
  Hirano I, et al. Gastroenterology 2024;166:1-10. doi: 10.1053/j.gastro.2023.09.004.
• Barrett's Esophagus in Eosinophilic Esophagitis in Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
  Scherer R, et al. Dig Dis. 2023;41:695-707. doi: 10.1159/000531060.
• Eosinophil Distribution in Eosinophilic Esophagitis and its Impact on Disease Activity and Response to Treatment.
  Godat A, et al. Clin Gastroenterol Hepatol. 2023 Dec 16:S1542-3565(23)01032-7. doi: 10.1016/j.cgh.2023.12.003.
• Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease Outcome.
  Heil A, et al. Int Arch Allergy Immunol. 2024;185:63-72. doi: 10.1159/000533815.
• Novel targets in EoE: one step forward?
  Straumann A, Greuter T. Gut 2023;72:811-812. doi: 10.1136/gutjnl-2022-327770
• Mechanisms and clinical management of eosinophilic oesophagitis: an overview.
  Biedermann L, Straumann A. Nat Rev Gastroenterol Hepatol 2023;20:101-119. doi: 10.1038/s41575-022-00691-x.

2022:

• Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). 
  Ma C, Schoepfer AM, et al. - J Allergy Clin Immunol 2022 Feb;149(2):659-670.  doi: 10.1016/j.jaci.2021.07.001.
  
• Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study.
  Greuter T, et al. - Allergy 2022 Jan 29. doi: 10.1111/all.15233.
• Reliability and Responsiveness of Endoscopic Disease Activity Assessment in Eosinophilic Esophagitis. 
  Ma C, et al. - Gastrointest Endosc. 2022 Feb 1:S0016-5107(22)00082-7. doi: 10.1016/j.gie.2022.01.014.
• International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. 
  Dellon ES, et al. - Clin Gastroenterol Hepatol. 2022 Feb 15:S1542-3565(22)00143-4. doi: 10.1016/j.cgh.2022.02.017.
• Management of eosinophilic esophagitis associated food impaction in Europe and the United States.
  Dis Esophagus. Schreiner P, et al. - 2022 Jan 28:doac003. doi: 10.1093/dote/doac003.
• Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. 
  Dellon ES, et al. - Clin Gastroenterol Hepatol. 2022 Feb 15:S1542-3565(22)00139-2. doi: 10.1016/j.cgh.2022.02.01.
• Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.
  Shoda T, et al. - Gastroenterology. 2022 Feb;162(2):439-453. doi: 10.1053/j.gastro.2021.10.016.
• A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
  Dellon ES, et al. Gastroenterology. 2022 Jul;163(1):59-76. doi: 10.1053/j.gastro.2022.03.02
• Disease Burden and Unmet Need in Eosinophilic Esophagitis.
  Bredenoord AJ, et al. Am J Gastroenterol. 2022 Aug 1;117(8):1231-1241. doi: 10.14309/ajg.0000000000001777
• Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study.
  Shoda T, et al. Gastroenterology. 2022 May;162(6):1635-1649. doi: 10.1053/j.gastro.2022.01.022
• A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
  Dellon ES, et al. J Allergy Clin Immunol. 2022 Jul;150(1):33-47. doi: 10.1016/j.jaci.2022.03.01
• Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis.
• Safroneeva E, et al. Clin Gastroenterol Hepatol. 2022 Apr;20(4):766-775.e4. doi: 10.1016/j.cgh.2021.05.049
• Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
  Miehlke S, et al. United European Gastroenterol J. 2022 Apr;10(3):330-343. doi: 10.1002/ueg2.12220.
• Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis.
  Bon L, et al. United European Gastroenterol J. 2022 Apr;10(3):308-318. doi: 10.1002/ueg2.12216
• Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference.
  Aceves SS, et al. Gastrointest Endosc. 2022 Oct;96(4):576-592.e1. doi: 10.1016/j.gie.2022.05.013
• Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis.
  Schreiner P, et al. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1729-1738.e1. doi: 10.1016/j.cgh.2021.11.009
• Diagnostic Delay in Patients With Eosinophilic Esophagitis Has Not Changed Since the First Description 30 Years Ago: Diagnostic Delay in Eosinophilic Esophagitis.
  Murray FR, et al. Am J Gastroenterol. 2022 Nov 1;117(11):1772-1779. doi: 10.14309/ajg.0000000000001950.
• IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis.
  Kaymak T, et al. Gut. 2022 May 25:gutjnl-2022-327166. doi: 10.1136/gutjnl-2022-327166

2021

• Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. Dis Esophagus. 
  Roth R, et al. - 2021 Sep 9;34(9):doab010. doi: 10.1093/dote/doab010. 
• Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. 
  Ma C, Schoepfer AM, Safroneeva E; COREOS Collaborators. - Gastroenterology. 2021 Sep;161(3):748-755. doi: 10.1053/j.gastro.2021.04.080. 
• Emerging Therapies for Eosinophilic Gastrointestinal Diseases.
  Peterson K, Safroneeva E, Schoepfer A. - J Allergy Clin Immunol Pract. 2021 Sep;9(9):3276-3281. doi: 10.1016/j.jaip.2021.07.031. 
• Food-induced immediate response of the esophagus-A newly identified syndrome in patients with eosinophilic esophagitis.
  Biedermann L, et al. - Allergy. 2021 Jan;76(1):339-347. doi: 10.1111/all.14495. Epub 2020 Aug 19. 
• Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study 
  Greuter T, et al. - Clin Gastroenterol Hepatol. 2021 Dec;19(12):2514-2523.e2. doi: 10.1016/j.cgh.2020.08.027. 
• Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis.
  Schoepfer AM, et al. - Gastrointest Endosc. 2021 Nov;94(5):912-919.e2. doi: 10.1016/j.gie.2021.05.017. 
• Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis. 
  Schreiner P, et al. - Clin Gastroenterol Hepatol. 2021 Nov 16:S1542-3565(21)01221-0. doi: 10.1016/j.cgh.2021.11.009. 
• Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. 
  Dellon ES, et al. - Clin Gastroenterol Hepatol. 2021 Mar;19(3):473-483.e17. doi: 10.1016/j.cgh.2020.03.036. 
• Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis. 
  Schoepfer AM, et al. Int Arch Allergy Immunol. 2021;182(12):1169-1193. doi: 10.1159/000516898. 
• Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis. 
  Safroneeva E, et al. - Clin Gastroenterol Hepatol. 2021 May 29:S1542-3565(21)00588-7. doi: 10.1016/j.cgh.2021.05.049.

2020

• Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis Gastroenterology. 
  Hirano I, et al. - 2020 Jan;158(1):111-122.e10. doi: 10.1053/j.gastro.2019.09.042. 
• Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. 
  Straumann A, et al. - Gastroenterology. 2020 Nov;159(5):1672-1685.e5. doi: 10.1053/j.gastro.2020.07.039. 
• Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). 
  Aceves S, et al. - J Allergy Clin Immunol. 2020 Jan;145(1):28-37. doi: 10.1016/j.jaci.2019.11.012. 
• Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis. 
  Safroneeva E, et al. - Am J Gastroenterol. 2020 Dec;115(12):2098-2102. doi: 10.14309/ajg.0000000000000957. 
• Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. 
  Schreiner P, et al. - Clin Gastroenterol Hepatol. 2020 Oct;18(11):2456-2462. doi: 10.1016/j.cgh.2019.11.057. 
• Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies. 
  Safroneeva E, et al. - Int Arch Allergy Immunol. 2020;181(3):211-220. doi: 10.1159/000504846. 
• Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. 
  Hirano I, et al. - Aliment Pharmacol Ther. 2020 Apr;51(8):750-759. doi: 10.1111/apt.15670.